A detailed history of Vanguard Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,826,546 shares of ESPR stock, worth $18.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,826,546
Previous 5,137,750 71.8%
Holding current value
$18.4 Million
Previous $15.4 Million 53.99%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.02 - $3.02 $7.45 Million - $11.1 Million
3,688,796 Added 71.8%
8,826,546 $23.7 Million
Q4 2023

Feb 14, 2024

BUY
$0.73 - $3.08 $289,363 - $1.22 Million
396,388 Added 8.36%
5,137,750 $15.4 Million
Q3 2023

Nov 14, 2023

BUY
$0.96 - $1.79 $458,973 - $855,793
478,097 Added 11.21%
4,741,362 $4.65 Million
Q2 2023

Aug 14, 2023

SELL
$1.2 - $1.76 $66,268 - $97,194
-55,224 Reduced 1.28%
4,263,265 $5.93 Million
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $84,716 - $423,582
58,025 Added 1.36%
4,318,489 $6.87 Million
Q4 2022

Feb 10, 2023

BUY
$5.09 - $8.5 $1.13 Million - $1.89 Million
221,939 Added 5.5%
4,260,464 $26.5 Million
Q3 2022

Nov 14, 2022

SELL
$5.45 - $8.13 $1.4 Million - $2.09 Million
-257,673 Reduced 6.0%
4,038,525 $27.1 Million
Q2 2022

Aug 12, 2022

SELL
$4.77 - $6.67 $931,733 - $1.3 Million
-195,332 Reduced 4.35%
4,296,198 $27.3 Million
Q1 2022

May 13, 2022

BUY
$3.34 - $5.56 $2.44 Million - $4.06 Million
730,091 Added 19.41%
4,491,530 $20.8 Million
Q4 2021

Feb 14, 2022

BUY
$4.81 - $11.92 $9.24 Million - $22.9 Million
1,921,196 Added 104.4%
3,761,439 $18.8 Million
Q3 2021

Nov 12, 2021

SELL
$11.34 - $21.37 $5.21 Million - $9.82 Million
-459,745 Reduced 19.99%
1,840,243 $22.2 Million
Q2 2021

Aug 13, 2021

BUY
$19.4 - $28.71 $44.6 Million - $66 Million
2,299,988 New
2,299,988 $48.6 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $139M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.